CAR-T Cell Therapy: How It Works, Who It Fits, and What Comes Next
Author: Reza Abdollahi · Reviewed by: CancerCareE Medical Team · Last updated: 2026-11-01 · Sources: 7
CAR-T is a form of cellular immunotherapy used mainly for certain blood cancers, with active research in solid tumors. This page explains the mechanism, the approved indications, the real risks, and the questions to ask a treating center. Country-specific access, cost and hospital details are on each destination page, not here.
Quick Answer
CAR-T works by collecting a patient's T-cells, genetically engineering them to recognize a specific protein on cancer cells, and reinfusing them after lymphodepletion. It is approved for several B-cell malignancies and multiple myeloma, and remains investigational for most solid tumors. The two main risks are cytokine release syndrome (CRS) and neurotoxicity (ICANS), both of which require experienced ICU-level management. Eligibility is decided only by the treating center's principal investigator, based on diagnosis, prior therapies, organ function, and performance status.
How CAR-T works
T-cells are collected from the patient's blood through leukapheresis, genetically modified in a laboratory to express a chimeric antigen receptor (CAR) against a chosen target, expanded, and reinfused after a short course of lymphodepleting chemotherapy. The engineered cells then recognize and kill cancer cells that express the target antigen.
| Step | What happens | Typical duration |
|---|---|---|
| 1. Evaluation | Diagnosis confirmation, organ function, disease burden, prior therapies. | 1–2 weeks |
| 2. Leukapheresis | T-cell collection via apheresis. | 1 day |
| 3. Manufacturing | Genetic modification and expansion in a GMP facility. | 3–4 weeks |
| 4. Bridging (if needed) | Disease control while cells are being manufactured. | Varies |
| 5. Lymphodepletion | Short chemotherapy to prepare the immune environment. | 3–5 days |
| 6. Infusion | CAR-T cells infused; monitoring begins immediately. | 1 day |
| 7. Monitoring | CRS and ICANS surveillance, often inpatient. | 2–4 weeks |
For the detailed treatment timeline, see the treatment process guide.
Approved indications vs clinical research
Regulatory status is jurisdiction-specific. A product approved by the FDA is not automatically approved by the EMA or NMPA, and vice versa. The same target can be approved in one disease and investigational in another.
| Status | Meaning | Access route |
|---|---|---|
| Approved | Authorized by a regulator (FDA, EMA, NMPA, etc.) for a defined disease, age group and line of therapy. | Commercial product through a licensed hospital. |
| Clinical trial | Under active evaluation in a registered study to determine safety and efficacy. | Enrollment through the trial's principal investigator. |
| Investigational (IIT or compassionate use) | Not approved in that jurisdiction; access limited to institutional programs. | Hospital-led program, eligibility decided case by case. |
Do not assume approval in one country means availability in another. This single point causes most misunderstandings between patients and hospitals.
Molecular targets
The choice of target depends on the cancer type and the tumor's antigen expression. The same target can be approved in one disease and investigational in another.
CD19
B-cell malignancies — approved for selected indications in most jurisdictions.
BCMA
Multiple myeloma — approved for selected indications in most jurisdictions.
Claudin18.2
Gastric, GEJ and pancreatic — investigational.
GPC3
Hepatocellular carcinoma — investigational.
CD22 / dual-target
B-cell malignancies — research-stage approaches.
Approved CAR-T products
The products below are approved by at least one major regulator. Jurisdiction-specific approvals and labels differ; the product page on each regulator's site is authoritative.
| Product | Generic | Target | Main approved indications | Regulator(s) |
|---|---|---|---|---|
| Kymriah | tisagenlecleucel | CD19 | B-ALL, DLBCL, FL | FDA, EMA |
| Yescarta | axicabtagene ciloleucel | CD19 | LBCL, FL | FDA, EMA |
| Tecartus | brexucabtagene autoleucel | CD19 | MCL, B-ALL | FDA, EMA |
| Breyanzi | lisocabtagene maraleucel | CD19 | LBCL, FL, CLL/SLL | FDA, EMA |
| Carvykti | ciltacabtagene autoleucel | BCMA | Multiple myeloma | FDA, EMA |
| Abecma | idecabtagene vicleucel | BCMA | Multiple myeloma | FDA, EMA |
China-specific products (Carteyva/Relma-cel, Fucaso/equecabtagene autoleucel) are NMPA-approved and covered on the China page: CAR-T therapy in China →. This reference page does not duplicate their pricing, hospitals or trial details.
Risks and long-term follow-up
CAR-T can cause serious, occasionally fatal, side effects. They are manageable only in centers with ICU-level support and trained staff.
The two risks that matter most
- CRS (cytokine release syndrome): fever, hypotension, hypoxia, and in severe cases organ dysfunction. Treated with tocilizumab and supportive care.
- ICANS (neurotoxicity): confusion, aphasia, seizures, cerebral edema. Managed with corticosteroids and neuro-critical care; tocilizumab is not a standalone treatment for isolated ICANS.
Ask any treating center in writing how many grade 3–4 CRS and ICANS cases they managed in the last 12 months, and what their tocilizumab and ICU availability is.
Other risks include prolonged cytopenias, B-cell aplasia with hypogammaglobulinemia (especially with CD19-targeted products), infection, and secondary malignancies. Long-term follow-up — typically up to 15 years in most jurisdictions — is required.
For the full side-effect profile, see the side effects guide.
Who is considered for CAR-T
Eligibility is decided by the treating center, not by referral platforms, not by family preference, and not by us. The factors below are the ones a center will actually look at.
Diagnosis and target
The disease must match an approved indication or an open trial protocol, and the tumor must express the target antigen.
Prior therapies
Most approvals require a defined number of prior lines. Trials often require failure of specific regimens.
Organ function
Cardiac, hepatic, renal and pulmonary reserve must be adequate for lymphodepletion and CRS management.
Performance status
ECOG status is a hard cutoff in most protocols. A very unwell patient cannot usually proceed.
Active infection
Uncontrolled infection is usually an exclusion until treated.
Neurological history
Prior significant CNS disease may exclude certain products or require additional monitoring.
For a deeper explanation, see the eligibility guide.
What happens if CAR-T does not work
Non-response and relapse are real outcomes. The next steps depend on the disease, the target, and what has already been tried.
- Re-biopsy to check for antigen loss (e.g., CD19 loss) or target change.
- Second cellular therapy — a different target or a dual-target product, in a trial or via an approved product.
- Bispecific antibodies where approved and appropriate for the disease.
- Allogeneic stem cell transplant in selected situations.
- Palliative or supportive care focused on quality of life, when further active therapy is not appropriate.
These are options to discuss with the treating center, not recommendations. The decision is individual.
Treatment destinations
This reference page does not publish country-specific pricing, hospital lists, or eligibility rules. Those are on each destination's CAR-T page, and each is written independently.
For the cross-country cost comparison, see CAR-T cost comparison.
Clinical trials as an access pathway
A trial is not the same as an approved treatment. Trials evaluate investigational products, new targets, or new treatment settings. Enrollment is decided by the trial's principal investigator, based on protocol criteria, not by patient preference.
CancerCareE does not manage clinical trial enrollment. Trial participation decisions are made by the principal investigator. For the general mechanism of trial matching, see the clinical trials guide. To search the registry directly: clinical trials guide. To search the registry directly: ClinicalTrials.gov.
Questions to ask a treating CAR-T center
These questions are not a script. They are the ones that most often separate a center that can manage CAR-T safely from one that cannot.
- What is the exact indication for this product in my situation, and is it approved or investigational in this country?
- What is the plan for bridging therapy if my disease progresses while the cells are being manufactured?
- How many grade 3–4 CRS and ICANS cases have you managed in the last 12 months, and what is your tocilizumab and ICU availability?
- What are the caregiver and proximity-to-center requirements after infusion?
- What long-term monitoring will be required, including management of cytopenias and immunoglobulin replacement?
- What happens if the first treatment does not achieve the expected response?
- What is the total estimated cost, what is included, and what additional costs should I plan for?
Frequently asked questions
What is CAR-T cell therapy?
CAR-T is a form of immunotherapy that uses a patient's own T-cells, collected by apheresis, genetically modified to target a specific protein on cancer cells, expanded in a laboratory, and reinfused after lymphodepletion. It is an established treatment for several blood cancers and remains investigational for most solid tumors.
Which cancers have approved CAR-T options?
Several CAR-T products are approved for selected B-cell acute lymphoblastic leukemia, B-cell lymphomas (including DLBCL, follicular lymphoma, mantle cell lymphoma), and multiple myeloma. The exact indication, age group, prior-treatment requirements and availability vary by product and by country. Check the regulator's label for the specific product in your jurisdiction.
What are CRS and ICANS?
Cytokine release syndrome (CRS) is a systemic inflammatory response ranging from fever to hypotension and hypoxia. Immune effector cell-associated neurotoxicity syndrome (ICANS) is a neurological syndrome with confusion, aphasia, seizures or cerebral edema. Both require experienced ICU-level management. Tocilizumab is used mainly for CRS; corticosteroids are used for ICANS; tocilizumab is not a standalone treatment for isolated ICANS.
Who decides whether I am eligible?
The treating center's principal investigator or treating oncologist decides, based on diagnosis, prior therapies, organ function, performance status, active infection, neurological history, and the specific protocol's inclusion and exclusion criteria. No intermediary, platform or agency can determine eligibility.
Is CAR-T available in my country?
Availability depends on whether the specific product is approved by your national regulator and whether a licensed center offers it. Approval in one country (for example the FDA in the US) does not mean the same product is available or approved elsewhere. Country-specific access is on each destination's CAR-T page.
Can CAR-T be repeated or combined with other treatments?
Yes, in selected situations. A second CAR-T, a different target, a bispecific antibody, or an allogeneic transplant may be considered after failure or relapse. Combination strategies are under active investigation. The decision is individualized and depends on the disease and the treating center's assessment.
How long is long-term follow-up?
Most regulators require long-term monitoring for up to 15 years after CAR-T infusion, to detect late effects including secondary malignancies and persistent immune deficits. Your treating center will share the follow-up schedule; your home oncologist should receive the records to continue monitoring after you return.
Sources
- U.S. Food and Drug Administration — Approved Cellular and Gene Therapy Products. fda.gov
- European Medicines Agency — CAR-T product information and approvals. ema.europa.eu
- National Medical Products Administration (NMPA), China — approved CAR-T product labels. nmpa.gov.cn
- U.S. National Library of Medicine — ClinicalTrials.gov, registry of CAR-T studies. clinicaltrials.gov
- American Society for Transplantation and Cellular Therapy (ASTCT) — consensus grading for CRS and ICANS. astct.org
- European Society for Blood and Marrow Transplantation (EBMT) — CAR-T patient management guidance. ebmt.org
- National Comprehensive Cancer Network (NCCN) — clinical practice guidelines in oncology. nccn.org
Start with a free informational review
Answer six questions about your diagnosis, prior treatments, and travel window. You will receive a short written summary of whether a CAR-T pathway exists for your case — and if not, what the alternatives are. No medical records are uploaded at this stage.
Start the free informational review →